Compare CRESY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | HELP |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | Argentina | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.3M | 862.2M |
| IPO Year | 1997 | 2020 |
| Metric | CRESY | HELP |
|---|---|---|
| Price | $10.74 | $10.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $15.86 | ★ $41.40 |
| AVG Volume (30 Days) | 206.5K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.26 | $3.76 |
| 52 Week High | $14.21 | $15.15 |
| Indicator | CRESY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 43.27 |
| Support Level | $10.52 | $9.97 |
| Resistance Level | $11.74 | $14.75 |
| Average True Range (ATR) | 0.42 | 0.93 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 19.21 | 21.68 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.